ASCEND Advancing syphilis control: elucidating novel dynamics for vaccine target discovery
- Coordinator
- London School of Hygiene and Tropical Medicine Royal Charter, United Kingdom
- Runs
- 1 September 2026 to 31 August 2031
- Status
- Running
- EU funding
- €1.4m
- Total cost
- €1.4m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101222010
What the project is doing
In the project's own words, from its summary on CORDIS.
Treponema pallidum (TP), the causative agent of syphilis, along with other pathogenic spirochetes, forms a distinct evolutionary clade with unique features including periplasmic endo-flagella, minimal genomes, and outer membranes lacking lipopolysaccharides. These features enable TP to navigate viscous environments, breach biological barriers, and evade host immune responses, leading to severe diseases affecting over 7 million people globally each year.
While vaccine development is vital to controlling syphilis, there is currently little consensus on effective vaccine targets. Clinically relevant strains and infection models are needed to deepen our understanding of TP's biology, without which vaccine progress will be challenging. This is urgent since syphilis infects 1 million pregnant women and causes 200,000 stillbirths annually, making it the second leading cause of stillbirths after malaria.
Research on TP is hindered by its dependence on host cells for growth, complicating in vitro cultivation and leaving critical questions unanswered. ASCEND will address these gaps by unraveling TP's distinctive biology and host interactions, using multi-omics approaches and cutting-edge techniques like spatial transcriptomics. Specifically, I will identify TP's host dependencies and optimize axenic (cell-free) culture conditions to isolate and grow TP directly from clinical samples, enabling the use of clinically relevant strains for experimentation.
Furthermore, I will identify TP adhesins and characterize their roles in attachment and cell cycle, positioning them as prime vaccine candidates to block infection at its earliest stage. Finally, skin organoids will be employed, for the first time, to investigate host-pathogen interactions in 3D under conditions that better mimic human disease than monolayer culture. Ultimately, ASCEND will seek to identify effective vaccine candidates and improve understanding of TP biology to combat syphilis
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| London School of Hygiene and Tropical Medicine Royal Charter | London | United Kingdom | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI